Market research
TD5A.F Tandem Diabetes Care, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 133.5
- Dividend yield
- Not available
- Beta
- 1.54
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- US8753722037
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 133.5
- Dividend yield
- Not available
- Beta
- 1.54
About
About Tandem Diabetes Care, Inc
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the TD5A.F discussion.
5 years, 5 months ago
Tandem Diabetes Care, Inc is currently in a long term uptrend where the price is trading 6.3% above its 200 day moving average.
From a valuation standpoint, the stock is 99.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 10.8.
Tandem Diabetes Care, Inc's total revenue rose by 55.0% to $168M since the same quarter in the previous year.
Its net income has increased by 541.0% to $17M since the same quarter in the previous year.
Finally, its free cash flow fell by 12.2% to $11M since the same quarter in the previous year.
Based on the above factors, Tandem Diabetes Care, Inc gets an overall score of 4/5.